D-RIBOSE

WHAT IS D-RIBOSE?

D-Ribose is a carbohydrate naturally found in all cells of the body.

D-Ribose is an essential pentose (5-carbon) sugar utilised by the body to synthesise DNA, RNA and produce energy.

Ribose metabolizes into 5-phosphoribosyl-1-pyrophosphate (PRPP), which is a rate-limiting substance used in the synthesis of nucleotides.

D-RIBOSE KEY BENEFITS

• Ideal for pre, intra or post workout
• Recommended by many Doctors and Practitioners
• Does not raise blood sugar levels
• Source of ATP.

Although we market D Ribose as a sports supplement, it is also widely recommended by specialist practitioners for sufferers of M.E. and related symptoms. We also supply D-Ribose under contract to many such practises.

SCIENTIFICALLY PROVEN

Carbohydrate has the following 'EFSA' Approved Claims.

• Carbohydrates contribute to the recovery of normal muscle function (contraction) after highly intensive and/or long-lasting physical exercise leading to muscle fatigue and the depletion of glycogen stores in skeletal muscle.

OTHER STUDIES

D-Ribose has also been studied in the USA to see if it helps with other health conditions. The EFSA does not recognise these claims.  They say there's not enough scientific evidence and therefore the claims cannot be used in the UK and Europe.

Please see excerpts below of one of these studies...

Jacob Teitelbaum*,1, Janelle Jandrain2 and Ryan McGrew3

The Open Pain Journal, 2012, 5, 32-37, Kona Research Center, 76-6326 Kaheiau St, Kailua Kona, Hawaii 96740, and Fibromyalgia and Fatigue Centers, Addison, Texas, USA; 2,3Schwabe North America, 3051 West Maple Loop Dr., Lehi, UT 84043, USA

Abstract: Objectives: Chronic Fatigue Syndrome and Fibromyalgia (CFS/FMS) are debilitating syndromes affecting ~2-4% of the population. Although they are heterogeneous conditions associated with many triggers, they appear to have the common pathology of being associated with impaired energy metabolism. As D-Ribose has been shown to increase cellular energy synthesis and was shown to significantly improve clinical outcomes in CFS/FMS in an earlier study, we hypothesized that giving D-Ribose would improve function in CFS/FMS patients.

Design, Location, and Subjects: An open-label, unblinded study in which 53 US clinics enrolled 257 patients who had been given a diagnosis of CFS/FMS by a health practitioner. Interventions: All subjects were given D-Ribose, a naturally occurring pentose carbohydrate, 5-g TID for 3 weeks. Outcome measures: All patients were assessed at baseline (1 week before treatment), and after 1,2, & 3 weeks using a Visual Analog Scale(1-7 points) rating energy, sleep, cognitive function, pain and overall well being.

Results: 203 patients completed the 3-week treatment trial. D-Ribose treatment led to both statistically (p<.0001) and clinically highly important average improvements in all categories:

• 61.3 % increase in energy
• 37% increase in overall well being
• 29.3% improvement in sleep
• 30% improvement in mental clarity
• 15.6% decrease in pain

Improvement began in the first week of treatment and continued to increase at the end of the 3 weeks of treatment. The D-Ribose was well tolerated.

Conclusions: In this multicenter study, D-Ribose resulted in markedly improved energy levels, sleep, mental clarity, pain relief, and wellbeing in patients suffering from fibromyalgia and chronic fatigue syndrome.